

Dr. Vinay Chopra
 MD (Pathology & Microbiology)
 Chairman & Consultant Pathologist

Dr. Yugam Chopra
 MD (Pathology)
 CEO & Consultant Pathologist

NAME	: Mrs. MEENAKSHI	PATIENT ID	: 1564874
AGE/ GENDER	: 47 YRS/FEMALE	REG. NO./LAB NO.	: 012407290069
COLLECTED BY	:	REGISTRATION DATE	: 29/Jul/2024 07:59 PM
REFERRED BY	:	COLLECTION DATE	: 29/Jul/2024 08:04PM
BARCODE NO.	: 01514093	REPORTING DATE	: 29/Jul/2024 09:43PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

ENDOCRINOLOGY

THYROID STIMULATING HORMONE (TSH)

THYROID STIMULATING HORMONE (TSH): SERUM 1.557 μ IU/mL 0.35 - 5.50

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

3rd GENERATION, ULTRASENSITIVE

INTERPRETATION:

AGE	REFERENCE RANGE (μ IU/mL)
0 – 5 DAYS	0.70 – 15.20
6 Days – 2 Months	0.70 – 11.00
3 – 11 Months	0.70 – 8.40
1 – 5 Years	0.70 – 7.00
6 – 10 Years	0.60 – 5.50
11 - 15	0.50 – 5.50
> 20 Years (Adults)	0.27 – 5.50
PREGNANCY	
1st Trimester	0.10 - 3.00
2nd Trimester	0.20 - 3.00
3rd Trimester	0.30 - 4.10

NOTE:- TSH levels are subjected to circadian variation, reaching peak levels between 2-4 a.m and at a minimum between 6-10 pm. The variation is of the order of 50 %. Hence time of the day has influence on the measured serum TSH concentration.

USE:- TSH controls biosynthesis and release of thyroid hormones T4 & T3. It is a sensitive measure of thyroid function, especially useful in early or subclinical hypothyroidism, before the patient develops any clinical findings or goitre or any other thyroid function abnormality.

INCREASED LEVELS:

- 1.Primary or untreated hypothyroidism, may vary from 3 times to more than 100 times normal depending on degree of hypofunction.
- 2.Hypothyroid patients receiving insufficient thyroid replacement therapy.
- 3.Hashimotos thyroiditis.
- 4.DRUGS: Amphetamines, Iodine containing agents and dopamine antagonist.
- 5.Neonatal period, increase in 1st 2-3 days of life due to post-natal surge.

DECREASED LEVELS:

- 1.Toxic multi-nodular goitre & Thyroiditis.
- 2.Over replacement of thyroid hormone in treatment of hypothyroidism.
- 3.Autonomously functioning Thyroid adenoma
- 4.Secondary pituitary or hypothalamic hypothyroidism
- 5.Acute psychiatric illness
- 6.Severe dehydration.




 DR.VINAY CHOPRA

CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)


 DR.YUGAM CHOPRA

CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY)



Dr. Vinay Chopra
 MD (Pathology & Microbiology)
 Chairman & Consultant Pathologist

Dr. Yugam Chopra
 MD (Pathology)
 CEO & Consultant Pathologist

NAME	: Mrs. MEENAKSHI	PATIENT ID	: 1564874
AGE/ GENDER	: 47 YRS/FEMALE	REG. NO./LAB NO.	: 012407290069
COLLECTED BY	:	REGISTRATION DATE	: 29/Jul/2024 07:59 PM
REFERRED BY	:	COLLECTION DATE	: 29/Jul/2024 08:04PM
BARCODE NO.	: 01514093	REPORTING DATE	: 29/Jul/2024 09:43PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

7.DRUGS: Glucocorticoids, Dopamine, Levodopa, T4 replacement therapy, Anti-thyroid drugs for thyrotoxicosis.

8.Pregnancy: 1st and 2nd Trimester

LIMITATIONS:

- 1.TSH may be normal in central hypothyroidism, recent rapid correction of hyperthyroidism or hypothyroidism, pregnancy, phenytoin therapy.
- 2.Autoimmune disorders may produce spurious results.




DR.VINAY CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)


DR.YUGAM CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY)



Dr. Vinay Chopra
 MD (Pathology & Microbiology)
 Chairman & Consultant Pathologist

Dr. Yugam Chopra
 MD (Pathology)
 CEO & Consultant Pathologist

NAME	: Mrs. MEENAKSHI	PATIENT ID	: 1564874
AGE/ GENDER	: 47 YRS/FEMALE	REG. NO./LAB NO.	: 012407290069
COLLECTED BY	:	REGISTRATION DATE	: 29/Jul/2024 07:59 PM
REFERRED BY	:	COLLECTION DATE	: 29/Jul/2024 08:04PM
BARCODE NO.	: 01514093	REPORTING DATE	: 29/Jul/2024 09:43PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
LUTEINISING HORMONE (LH)			
LUTEINISING HORMONE (LH): SERUM <i>by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)</i>	6.96	mIU/mL	MALES: 0.57 - 12.07 FOLLICULAR PHASE: 1.80 - 11.78 MID-CYCLE PEAK: 7.59 - 89.08 LUTEAL PHASE: 0.56 - 14.0 POST MENOPAUSAL WITHOUT HRT: 5.16 - 61.99

INTERPRETATION:

- Luteinizing hormone (LH) is a glycoprotein hormone consisting of 2 non covalently bound subunits (alpha and beta). Gonadotropin-releasing hormone from the hypothalamus controls the secretion of the gonadotropins, FSH and LH, from the anterior pituitary.
- In both males and females, LH is essential for reproduction. In females, the menstrual cycle is divided by a mid cycle surge of both LH and FSH into a follicular phase and a luteal phase.
- This "LH surge" triggers ovulation thereby not only releasing the egg, but also initiating the conversion of the residual follicle into a corpus luteum that, in turn, produces progesterone to prepare the endometrium for a possible implantation.
- LH supports thecal cells in the ovary that provide androgens and hormonal precursors for estradiol production. LH in males acts on testicular interstitial cells of Leydig to cause increased synthesis of testosterone.

The test is useful in the following situations:

- An adjunct in the evaluation of menstrual irregularities.
- Evaluating patients with suspected hypogonadism
- Predicting ovulation & Evaluating infertility
- Diagnosing pituitary disorders
- In both males and females, primary hypogonadism results in an elevation of basal follicle-stimulating hormone and luteinizing hormone levels.

FSH AND LH ELEVATED IN:

- Primary gonadal failure
- Complete testicular feminization syndrome
- Precocious puberty (either idiopathic or secondary to a central nervous system lesion)
- Menopause
- Primary ovarian hypo dysfunction in females
- Polycystic ovary disease in females
- Primary hypogonadism in males

LH IS DECREASED IN:

- Primary ovarian hyper function in females
- Primary hypergonadism in males

NOTE

- FSH and LH are both decreased in failure of the pituitary or hypothalamus.




 DR. VINAY CHOPRA

CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)


 DR. YUGAM CHOPRA

CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY)



Dr. Vinay Chopra
 MD (Pathology & Microbiology)
 Chairman & Consultant Pathologist

Dr. Yugam Chopra
 MD (Pathology)
 CEO & Consultant Pathologist

NAME	: Mrs. MEENAKSHI	PATIENT ID	: 1564874
AGE/ GENDER	: 47 YRS/FEMALE	REG. NO./LAB NO.	: 012407290069
COLLECTED BY	:	REGISTRATION DATE	: 29/Jul/2024 07:59 PM
REFERRED BY	:	COLLECTION DATE	: 29/Jul/2024 08:04PM
BARCODE NO.	: 01514093	REPORTING DATE	: 29/Jul/2024 09:43PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

FOLLICLE STIMULATING HORMONE (FSH)

FOLLICLE STIMULATING HORMONE (FSH): SERUM by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)	18.53	mIU/mL	FEMALE FOLLICULAR PHASE: 3.03 - 8.08 FEMALE MID-CYCLE PEAK: 2.55 - 16.69 FEMALE LUTEAL PHASE: 1.38 - 5.47 FEMALE POST-MENOPAUSAL: 26.72 - 133.41 MALE: 0.95 - 11.95
--	-------	--------	---

INTERPRETATION:

- Gonadotropin-releasing hormone from the hypothalamus controls the secretion of the gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary.
- The menstrual cycle is divided by a midcycle surge of both FSH and LH into a follicular phase and a luteal phase.
- FSH appears to control gametogenesis in both males and females.

The test is useful in the following settings:

- An adjunct in the evaluation of menstrual irregularities.
- Evaluating patients with suspected hypogonadism.
- Predicting ovulation
- Evaluating infertility
- Diagnosing pituitary disorders
- In both males and females, primary hypogonadism results in an elevation of basal follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels.

FSH and LH LEVELS ELEVATED IN:

- Primary gonadal failure
- Complete testicular feminization syndrome.
- Precocious puberty (either idiopathic or secondary to a central nervous system lesion)
- Menopause (postmenopausal FSH levels are generally >40 IU/L)
- Primary ovarian hypofunction in females
- Primary hypogonadism in males

NOTE:

- Normal or decreased FSH is seen in polycystic ovarian disease in females
- FSH and LH are both decreased in failure of the pituitary or hypothalamus.




 DR. VINAY CHOPRA

CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)


 DR. YUGAM CHOPRA

CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME : Mrs. MEENAKSHI
AGE/ GENDER : 47 YRS/FEMALE
COLLECTED BY :
REFERRED BY :
BARCODE NO. : 01514093
CLIENT CODE. : KOS DIAGNOSTIC LAB
CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

PATIENT ID : 1564874
REG. NO./LAB NO. : 012407290069
REGISTRATION DATE : 29/Jul/2024 07:59 PM
COLLECTION DATE : 29/Jul/2024 08:04 PM
REPORTING DATE : 29/Jul/2024 09:43 PM

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

PROLACTIN

PROLACTIN: SERUM 16.47 ng/mL 3 - 25
by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

INTERPRETATION:

1. Prolactin is secreted by the anterior pituitary gland and controlled by the hypothalamus.
2. The major chemical controlling prolactin secretion is dopamine, which inhibits prolactin secretion from the pituitary.
3. Physiological function of prolactin is the stimulation of milk production. In normal individuals, the prolactin level rises in response to physiologic stimuli such as sleep, exercise, nipple stimulation, sexual intercourse, hypoglycemia, postpartum period, and also is elevated in the newborn infant.

INCREASED (HYPERPROLACTEMIA):

1. Prolactin-secreting pituitary adenoma (prolactinoma, which is 5 times more frequent in females than males).
2. Functional and organic disease of the hypothalamus.
3. Primary hypothyroidism.
4. Section compression of the pituitary stalk.
5. Chest wall lesions and renal failure.
6. Ectopic tumors.
7. DRUGS:- Anti-Dopaminergic drugs like antipsychotic drugs, anti-nausea/antiemetic drugs, Drugs that affect CNS serotonin metabolism, serotonin receptors, or serotonin reuptake (anti-depressants of all classes, ergot derivatives, some illegal drugs such as cannabis), Antihypertensive drugs, Opiates, High doses of estrogen or progesterone, anticonvulsants (valproic acid), anti-tuberculous medications (Isoniazid).

SIGNIFICANCE:

1. In loss of libido, galactorrhea, oligomenorrhea, hyperprolactinemia often results in amenorrhea or menorrhagia, and infertility in premenopausal females.
2. Loss of libido, impotence, infertility, and hypogonadism in males. Postmenopausal and premenopausal women, as well as men, can also suffer from decreased muscle mass and osteoporosis.
3. In males, prolactin levels >13 ng/mL are indicative of hyperprolactinemia.
4. In women, prolactin levels >27 ng/mL in the absence of pregnancy and postpartum lactation are indicative of hyperprolactinemia.
5. Clear symptoms and signs of hyperprolactinemia are often absent in patients with serum prolactin levels <100 ng/mL.
4. Mild to moderately increased levels of serum prolactin are not a reliable guide for determining whether a prolactin-producing pituitary adenoma is present, 5. Whereas levels >250 ng/mL are usually associated with a prolactin-secreting tumor.

CAUTION:

Prolactin values that exceed the reference values may be due to macroprolactin (prolactin bound to immunoglobulin). Macroprolactin should be evaluated if signs and symptoms of hyperprolactinemia are absent, or pituitary imaging studies are not informative.

*** End Of Report ***



DR. VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR. YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY)

